NCT05328505 Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer
| NCT ID | NCT05328505 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2022-08-23 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2022-08-23 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase II prospective single-arm trial that is recruiting 80 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET. Participants of this study will receive molecular imaging informed radiation dose escalation to site of recurrent disease and de-escalation to uninvolved areas. Participants will be follow-up as per standard of care up to 5 years post-treatment.
Eligibility Criteria
Inclusion Criteria: * Men older than 18 years old. * Histologically proven initial diagnosis of adenocarcinoma prostate cancer. * Previous radical prostatectomy. * Biochemical relapse with local or regional recurrence proven on PSMA PET. * Five or less positive nodes on the PSMA PET. * ECOG 0-1 Exclusion Criteria: * Presence of para-aortic lymph nodes or distant metastasis. * Chronic pelvic inflammatory disease. * Contraindication for radiation treatment. * Previous radiation treatment within the pelvis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05328505 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05328505 currently recruiting?
Yes, NCT05328505 is actively recruiting participants. Contact the research team at andrew.mcpartlin@uhn.ca for enrollment information.
Where is the NCT05328505 trial being conducted?
This trial is being conducted at London, Canada, Toronto, Canada.
Who is sponsoring the NCT05328505 clinical trial?
NCT05328505 is sponsored by University Health Network, Toronto. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.